Enlivex (ENLV) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex Therapeutics has announced the successful dosing of the first patient in a Phase I trial to test Allocetra, a potential new treatment for psoriatic arthritis. The study aims to recruit six patients unresponsive to conventional therapies, exploring Allocetra’s safety and therapeutic effects. This development could position Enlivex at the forefront of addressing significant unmet needs in a growing psoriatic arthritis market.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.